Clinical Trial Update: 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients

View source ↗

Summary

A completed clinical trial evaluating 68Ga-FAPI-46 PET/CT to predict response to neoadjuvant therapy in nasopharyngeal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• 68Ga-FAPI-46 (Gallium-68-labeled FAPI-46)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Nasopharyngeal Cancer | Status: COMPLETED